News | May 22, 2024
AstraZeneca sets ambition to deliver US$ 80 billion revenue by 2030
Launch of 20 new medicines expected by 2030
Launch of 20 new medicines expected by 2030
EBITDA before special items falls 1.3 percent to € 4.41 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Sales reflect continued strong growth in oncology and vaccines
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Pharma Solutions operates 10 research and development and/or production sites globally
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Subscribe To Our Newsletter & Stay Updated
